0000950170-23-032324.txt : 20230710 0000950170-23-032324.hdr.sgml : 20230710 20230710070514 ACCESSION NUMBER: 0000950170-23-032324 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20230710 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230710 DATE AS OF CHANGE: 20230710 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001314102 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 262774444 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51122 FILM NUMBER: 231078217 BUSINESS ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-926-5000 MAIL ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: pSivida Corp. DATE OF NAME CHANGE: 20080619 FORMER COMPANY: FORMER CONFORMED NAME: pSivida LTD DATE OF NAME CHANGE: 20050111 8-K 1 eypt-20230710.htm 8-K 8-K
0001314102false00013141022023-07-102023-07-10

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 10, 2023

 

 

EyePoint Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

000-51122

26-2774444

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

480 Pleasant Street

 

Watertown, Massachusetts

 

02472

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (617) 926-5000

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.001

 

EYPT

 

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Nancy S. Lurker Employment Matters

Effective as of July 10, 2023 (the “Lurker Transition Date”), Nancy S. Lurker transitioned from her role as Chief Executive Officer of EyePoint Pharmaceuticals, Inc. (the “Company”) to Executive Vice Chair of the Company. Ms. Lurker will report to the Board of Directors of the Company (the “Board”) and serve as an advisor to Jay S. Duker, M.D., the Company’s newly-appointed President and Chief Executive Officer. Ms. Lurker will continue to serve as a member of the Board and was appointed to serve as the Vice Chair of the Board as of the Lurker Transition Date.

In connection with Ms. Lurker’s transition, the Company and Ms. Lurker entered into an amendment (the “Lurker Amendment”) to that certain Employment Letter Agreement, dated September 15, 2016, as amended by that certain First Amendment to Employment Letter Agreement, effective as of January 3, 2023, by and between the Company and Ms. Lurker (as amended, the “Lurker Employment Agreement”). The Lurker Amendment provides that Ms. Lurker will serve as Executive Vice Chair for one year from the Lurker Transition Date (the “Initial Term”), subject to an extension of up to six months upon the expiration of the Initial Term by the Board at its sole discretion (if exercised by the Board, the “Extension Term” and together with the Initial Term, the “Term”). Under the Lurker Amendment, expiration of the Term will not constitute a termination of employment by the Company without Cause (as defined in the Lurker Employment Agreement) or constitute grounds for Ms. Lurker to terminate her employment for Good Cause (as defined in the Lurker Employment Agreement).

Pursuant to the Lurker Amendment, Ms. Lurker’s annual base salary was adjusted to $455,000 and her target bonus was adjusted to 45% of her annual base salary. Ms. Lurker’s bonus in respect of calendar year 2023 will be calculated based upon a blended rate base salary and blended target bonus, which factors in her base salary and target bonus rates in effect during calendar year 2023 for Ms. Lurker’s service as Chief Executive Officer and for her service as Executive Vice Chair, pro-rated based on the portion of calendar year 2023 during which she served in each such position.

In connection with Ms. Lurker’s transition, the Company also granted to Ms. Lurker, subject to the terms and conditions of the EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan (the “2023 Plan”) and the applicable underlying award agreements, (a) an award of stock options (“Options”) to purchase 66,666 shares of common stock of the Company (“Common Stock”), which Options shall vest one-quarter on the first anniversary of the Lurker Transition Date and in equal monthly installments thereafter until vested in full on the fourth anniversary of the Lurker Transition Date, and (b) an award of 33,334 restricted stock units (“RSUs”) vesting one-third on the date that is 12 months following the Lurker Transition Date, one-third on the date that is 24 months following the Lurker Transition Date and one-third on the date that is 36 months following the Lurker Transition Date. The exercise price of the shares of Common Stock underlying the Options is equal to the closing price of the shares of Common Stock on the Nasdaq Stock Market on the Lurker Transition Date.

The description of the Lurker Amendment contained herein does not purport to be complete and is qualified in its entirety by reference to the complete text of the Lurker Amendment, a copy of which is filed as Exhibit 10.1 to this current report on Form 8-K.

Jay S. Duker, M.D. Employment Matters and Board Appointment

In connection with Ms. Lurker’s transition from Chief Executive Officer of the Company to Executive Vice Chair of the Company, the Company appointed Dr. Duker as the Company's President and Chief Executive Officer, effective as of July 10, 2023 (the “Duker Start Date”). As of the Duker Start Date, the Board also (i) increased the size of the Board by one member to nine directors and (ii) appointed Dr. Duker to fill the vacancy for the newly created directorship resulting from the increase in the number of directors, to serve until the Company's 2024 annual meeting of stockholders and until his successor has been designated or appointed and qualified, as the case may be, or until his earlier death, resignation or removal.

Dr. Duker, age 65, has served as the Company’s President and Chief Operating Officer since January of 2023 and Chief Operating Officer since November 2021. Dr. Duker served as the Company’s Chief Strategic Scientific Officer on a part-time basis in 2020, after having served as an independent member of the Board since 2016. Dr. Duker was the Director of the New England Eye Center from 2001 to 2021 and Chair of Ophthalmology at Tufts Medical Center and the Tufts University School of Medicine over the same period. Dr. Duker has co-founded three start-ups, including Hemera Biosciences, a gene therapy company that developed an anti-complement treatment for dry macular degeneration, which was acquired by Janssen in 2020. In addition, Dr. Duker was the Chair of the Board of Sesen Bio, a publicly traded clinical stage biopharmaceutical company until March 2023. He is currently on the Board of Hubble Bio. He has published more than 300 journal articles related to ophthalmology and is co-author of Yanoff and Duker’s Ophthalmology, a best-selling ophthalmic textbook. Dr. Duker received an A.B. from Harvard University and an M.D. from the Jefferson Medical College of Thomas Jefferson University.

In connection with Dr. Duker’s appointment to President and Chief Executive Officer, the Company and Dr. Duker entered into an amendment (the “Duker Amendment”) to that certain Amended and Restated Employment Agreement, effective as of November 1, 2021, as amended by that certain First Amendment to Employment Letter Agreement, effective as of January 3, 2023, by and between the Company and Dr. Duker (as amended, the “Duker Employment Agreement”).

Pursuant to the Duker Amendment, Dr. Duker is entitled to receive an annual base salary of $650,000, subject to increase from time to time, and an annual cash bonus, which is based on the achievement of individual and corporate performance objectives, calculated as a percentage of his annual base salary, and which will be determined by the Board, in its sole discretion. The Duker Amendment provides that Dr. Duker’s target annual bonus is 60% of his annual base salary and his bonus in respect of calendar year 2023 will be calculated based upon a blended rate annual base salary and blended target bonus, which factors in Dr. Duker’s base salary and target bonus rates in effect during calendar year 2023 for his service as President and Chief Operating officer and for his service as President and Chief Executive Officer, pro-rated based on the portion of calendar year 2023 during which he served in each such position.

On the Duker Start Date, the Company also granted Dr. Duker, subject to the terms and conditions of the 2023 Plan and the applicable underlying award agreements, (a) Options to purchase 100,000 shares of Common Stock, which Options shall vest one-quarter on the first anniversary of the Duker Start Date and in equal monthly installments thereafter until vested in full on the fourth anniversary of the Duker Start Date, and (b) an award of 50,000 RSUs vesting one-third on the date that is 12 months following the Duker Start Date, one-third on the date that is 24 months following the Duker Start Date and one-third on the date that is 36 months following the Duker Start Date. The exercise price of the shares of Common Stock underlying the Options is equal to the closing price of the shares of Common Stock on the Nasdaq Stock Market on the Duker Start Date.

There is no arrangement or understanding between Dr. Duker and any other person pursuant to which Dr. Duker was appointed a director of the Company. There are no relationships or transactions in which Dr. Duker has or will have an interest, or was or is a party, requiring disclosure under Item 404(a) of Regulation S-K.

The description of the Duker Amendment contained herein does not purport to be complete and is qualified in its entirety by reference to the complete text of the Duker Amendment, a copy of which is filed as Exhibit 10.2 to this current report on Form 8-K.

Item 8.01 Other Events.

On July 10, 2023, the Company issued a press release announcing the transition of Ms. Lurker from Chief Executive Officer to Executive Vice Chair and the appointment of Dr. Duker as President, Chief Executive Officer and Director. A copy of the press release is filed with this Current Report on Form 8-K as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.

 

Description

 

10.1

 

Second Amendment to Employment Agreement, dated July 10, 2023, by and between EyePoint Pharmaceuticals, Inc. and Nancy S. Lurker

10.2

 

Second Amendment to Employment Agreement, dated July 10, 2023, by and between EyePoint Pharmaceuticals, Inc. and Jay S. Duker

99.1

 

Press Release of EyePoint Pharmaceuticals, Inc. dated July 10, 2023

104

 

Cover Page Interactive Data File (embedded within the inline XBRL document)

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

EYEPOINT PHARMACEUTICALS, INC.

 

 

 

 

Date:

July 10, 2023

By:

/s/ George O. Elston

 

 

 

George O. Elston
Chief Financial Officer

 

 EX-10.1 2 eypt-ex10_1.htm EX-10.1 EX-10.1

 

Exhibit 10.1

 

SECOND amendment to employment LETTER agreement

SECOND AMENDMENT TO EMPLOYMENT LETTER AGREEMENT (this “Amendment”), dated as of July 10, 2023, between EyePoint Pharmaceuticals, Inc. (the “Company”), and Nancy S. Lurker (“Employee”).

 

W I T N E S S E T H

WHEREAS, the Company and Employee have previously entered into that certain employment letter agreement, dated September 15, 2016, as amended by that certain First Amendment to Employment Letter Agreement, effective as of January 3, 2023 (collectively, the “Employment Agreement”);

 

WHEREAS, the Company and Employee desire to enter into this Amendment to modify certain provisions of the Employment Agreement.

 

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the parties hereto agree as follows:

 

1.
Definitions. Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed thereto in the Employment Agreement.

 

2.
Position and Duties; Initial Term; Extension Term.

 

(a) References in the Employment Agreement to Employee’s title as “Chief Executive Officer” are hereby amended to state that, as of July 10, 2023 (the “Executive Vice Chair Start Date”), Employee’s title is that of “Executive Vice Chair.” Employee shall report to the Board of Directors and serve as an advisor to the Chief Executive Officer of the Company at the Chief Executive Officer’s request. As of the Executive Vice Chair Start Date, Employee shall also be appointed to serve as the Vice Chair of the Board of Directors of the Company. Employee’s position as Executive Vice Chair shall have a term of one (1) year from the Executive Vice Chair Start Date (the “Initial Term”), subject to an extension of up to six (6) months upon the expiration of the Initial Term by the Board of Directors at its sole discretion (the “Extension Term”). References to the “Term” herein shall mean the Initial Term as extended by the Extension Term, if exercised by the Board. Upon expiration of the Term, Employee shall no longer be employed as an employee of the Company. Employee agrees and acknowledges that the expiration of the Term shall not (i) constitute a termination of employment by the Company without Cause or (ii) constitute grounds for Employee to terminate Employee’s employment for Good Cause. Further, Employee agrees and acknowledges that, upon expiration of the Term, Employee shall not have any further rights to severance payments or benefits pursuant to Section 5(b) or Section 5(c) of the Employment Agreement. Employee further

MACROBUTTON DocID \\4160-5597-0632 v7

 

agrees that the change in position and duties described herein shall not constitute grounds for Employee to terminate Employee’s employment for Good Cause.

 

(b) The last sentence of subsection (a) of Section 1 of the Employment Agreement is hereby deleted in its entirety and replaced with the following: “If your employment with the Company terminates for any reason, then concurrently with such termination, you will be deemed to have resigned from any director, officer, trustee, or other positions you may hold with the Company’s subsidiaries, or any of their respective related committees, trusts, or other similar entities, in each case unless otherwise agreed in writing by the Company and you.”

 

3.
Base Salary; Bonus Compensation; Equity Grant. References in the Employment Agreement to Employee’s Base Salary, Target Bonus and sign-on equity grant are hereby amended as follows, with effect from and after the Executive Vice Chair Start Date:

 

(a) Base Salary. Employee’s Base Salary shall be paid at the rate of $455,000 per year, payable in accordance with the regular payroll practices of the Company

 

(b) Bonus Compensation. Employee’s Target Bonus is amended to reflect a Target Bonus of 45% of the Base Salary. Notwithstanding anything herein to the contrary, Employee’s bonus in respect of calendar year 2023 shall be calculated based upon a blended rate Base Salary and blended Target Bonus, which factors in Employee’s Base Salary and Target Bonus rates in effect during calendar year 2023 for Employee’s service as Chief Executive Officer and for Employee’s service as Executive Vice Chair, pro-rated based on the portion of calendar year 2023 during which Employee served in each such position.

 

(c) Equity Grant. On the Executive Vice Chair Start Date, Employee will be granted (A) an award of 66,666 options (“Options”) to purchase common stock (“Stock”) with time-based vesting (i) one-quarter on the first anniversary of the grant date and (ii) in equal monthly installments thereafter until vested in full on the fourth anniversary of the grant date; and (B) an award of 33,334 restricted stock units (“RSUs”) with time-based vesting (i) one-third on the date that is twelve (12) months following the RSU grant date, and (ii) one-third on the date that is twenty-four (24) months following the RSU grant date and (iii) one-third on the date that is thirty-six (36) months following the RSU grant date. The Options and RSUs shall be subject to the terms and conditions of the 2023 Long-Term Incentive Plan and the underlying award agreements.

 

4.
Definition of Good Cause. Section 4(c) of the Employment Agreement is hereby deleted in its entirety and replaced with the following:

 

(c) By You for Good Cause. You may terminate your employment for Good Cause by (A) providing notice to the Company specifying in

MACROBUTTON DocID \\4160-5597-0632 v7

 

reasonable detail the condition giving rise to the Good Cause no later than the thirtieth (30th) day following your first becoming aware of such event or condition; (B) providing the Company a period of (30) days to remedy the event or condition; and (C) terminating your employment for Good Cause within thirty (30) days following the expiration of the period to remedy if the Company fails to remedy the condition. The following, if occurring without your written consent, shall constitute “Good Cause” for termination by you: (i) a material diminution in the nature or scope of your position, duties, or authority including reporting responsibilities (other than temporarily while you are physically or mentally incapacitated to such a degree that you would be eligible for disability benefits under the Company’s disability income plan or as required by applicable law); (ii) a material reduction in the Base Salary or the Target Bonus opportunity; (iii) a material breach by the Company of this Agreement; or (iv) a requirement by the Company that you relocate to a location more than fifty (50) miles from your primary residence as of the Executive Vice Chair Start Date.

 

5.
Continued Effectiveness of the Employment Agreement. The Employment Agreement is, and shall continue to be, in full force and effect, except as otherwise provided in this Second Amendment and except that all references to the Employment Agreement set forth in the Employment Agreement and any other agreements to which the parties hereto are parties that have been executed prior to the date hereof shall mean the Employment Agreement, as amended by this Second Amendment.

 

6.
Miscellaneous.

 

(a)
Governing Law. This Amendment shall be governed by, and construed in accordance with, the laws of the Commonwealth of Massachusetts, without regard to its conflicts of law principles thereof.
(b)
Counterparts. This Amendment may be executed in one or more counterparts, each of which shall be deemed an original and all of which taken together shall constitute one and the same instrument.
(c)
Construction. This Amendment shall be construed without regard to any presumption or other rule requiring construction against the drafting party.

 

[Signature Page Follows]

 

MACROBUTTON DocID \\4160-5597-0632 v7

 

IN WITNESS WHEREOF, the parties have executed this Amendment on the date first set forth above.

 

 

EYEPOINT PHARMACEUTICALS, INC.

 

 

 

By_/s/ Jennifer Leonard___________________

Name: Jennifer Leonard

Title: Chief People Officer & SVP IT

 

 

 

/s/ Nancy Lurker_________________________

Nancy S. Lurker

 

 

 

MACROBUTTON DocID \\4160-5597-0632 v7

EX-10.2 3 eypt-ex10_2.htm EX-10.2 EX-10.2

 

Exhibit 10.2

 

SECOND amendment to employment agreement

SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), dated as of July 10, 2023, between EyePoint Pharmaceuticals, Inc. (the “Company”), and Jay S. Duker, M.D. (“Employee”).

 

W I T N E S S E T H

WHEREAS, the Company and Employee have previously entered into that certain Amended and Restated Employment Agreement, effective as of November 1, 2021, as amended by that certain First Amendment to Employment Agreement, effective as of January 3, 2023 (collectively, the “Employment Agreement”);

 

WHEREAS, the Company and Employee desire to enter into this Second Amendment to modify certain provisions of the Employment Agreement.

 

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the parties hereto agree as follows:

 

1.
Definitions. Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed thereto in the Employment Agreement.

 

2.
Position and Duties. Subsection (a) of Section 1 of the Employment Agreement is hereby deleted in its entirety and the following substituted in lieu thereof.

 

(a)
As of July 10, 2023 (the “President & CEO Start Date”), Employee is promoted to the role of President and Chief Executive Officer, reporting to the Board of Directors of the Company. This is an exempt position. As of the President & CEO Start Date, Employee shall also be appointed to serve as a member of the Board of Directors of the Company. During Employee’s employment, Employee may be asked from time to time, to serve as a director or officer of one or more of the Company's subsidiaries, in each case, without further compensation. If Employee’s employment with the Company terminates for any reason, then concurrently with such termination, Employee will be deemed to have resigned from any director, officer, trustee, or other positions Employee may hold with the Company, the Company's subsidiaries, or any of their respective related committees, trusts, or other similar entities, in each case unless otherwise agreed in writing by the Company and Employee.

 

3.
Subsections (a), (b) and (c) of Section 2 of the Employment Agreement are hereby deleted in their entirety and the following substituted in lieu thereof.

 

(a)
Base Salary. The Company will pay Employee a base salary at the rate of $650,000 per year, payable in accordance with the regular payroll practices of the Company (as may be increased, from time to time, the "Base Salary").

MACROBUTTON DocID \\4146-9655-7384 v6

 

 

(b)
Bonus Compensation. For each fiscal year completed during Employee’s employment under this Agreement, Employee will be eligible for an annual cash bonus. With effect from the President & CEO Start Date, Employee’s target bonus will be 60% of the Base Salary (the "Target Bonus"), with the actual amount of any such bonus being determined by the Board of Directors of the Company (the "Board") in its sole discretion, based on Employee’s performance and that of the Company against goals established by the Board (and for the goals based on Employee’s performance, agreed to by Employee) and consistent with any applicable plan or program documents and generally applicable Company policies. Notwithstanding anything herein to the contrary, Employee’s bonus in respect of calendar year 2023 shall be calculated based upon a blended rate Base Salary and blended Target Bonus, which factors in Employee’s Base Salary and Target Bonus rates in effect during calendar year 2023 for Employee’s service as President and Chief Operating Officer and for Employee’s service as President & CEO, pro-rated based on the portion of calendar year 2023 during which Employee served in each such position. Except as otherwise expressly provided in Section 4 hereof, Employee must be employed through the end of the fiscal year to which a bonus relates in order to earn the bonus. Subject to Section 4 of this Agreement, if Employee’s employment terminates, for any reason, prior to the end of the fiscal year to which a bonus relates, the bonus is not earned.

 

(c)
President & CEO Equity Grants. On the President & CEO Start Date, Employee will be granted (A) a new award of 100,000 options (“Options”) to purchase common stock (“Stock”) with time-based vesting (i) one-quarter on the first anniversary of the grant date and (ii) in equal monthly installments thereafter until vested in full on the fourth anniversary of the grant date; and (B) an award of 50,000 restricted stock units (“RSUs”) with time-based vesting (i) one-third on the date that is twelve (12) months following the RSU grant date, and (ii) one-third on the date that is twenty-four (24) months following the RSU grant date and (iii) one-third on the date that is thirty-six (36) months following the RSU grant date. The Options and RSUs shall be subject to the terms and conditions of the 2023 Long-Term Incentive Plan and the underlying award agreements.

 

4.
Continued Effectiveness of the Employment Agreement. The Employment Agreement is, and shall continue to be, in full force and effect, except as otherwise provided in this Second Amendment and except that all references to the Employment Agreement set forth in the Employment Agreement and any other agreements to which the parties hereto are parties that have been executed prior to the date hereof shall mean the Employment Agreement, as amended by this Second Amendment.

 

MACROBUTTON DocID \\4146-9655-7384 v6

 

5.
Miscellaneous.

 

(a)
Governing Law. This Amendment shall be governed by, and construed in accordance with, the laws of the Commonwealth of Massachusetts, without regard to its conflicts of law principles thereof.
(b)
Counterparts. This Amendment may be executed in one or more counterparts, each of which shall be deemed an original and all of which taken together shall constitute one and the same instrument.
(c)
Construction. This Amendment shall be construed without regard to any presumption or other rule requiring construction against the drafting party.

 

[Signature Page Follows]

 

MACROBUTTON DocID \\4146-9655-7384 v6

 

IN WITNESS WHEREOF, the parties have executed this Amendment on the date first set forth above.

 

 

EYEPOINT PHARMACEUTICALS, INC.

 

 

 

By_/s/ Jennifer Leonard__________________

Name: Jennifer Leonard

Title: Chief People Officer & SVP IT

 

 

 

/s/ Jay Duker____________________________

Jay S. Duker, M.D.

 

 

MACROBUTTON DocID \\4146-9655-7384 v6

EX-99.1 4 eypt-ex99_1.htm EX-99.1 EX-99.1

img96707757_0.jpg 

Exhibit 99.1

 

EyePoint Pharmaceuticals Announces Chief Executive Officer Transition

 

–
Jay S. Duker, M.D., Previously President and Chief Operating Officer, Appointed President and Chief Executive Officer –

 

–
Nancy S. Lurker Transitions to Executive Vice Chair of the Board of Directors Pursuant to Long Term Succession Plan

 

 

WATERTOWN, Mass., July 10, 2023 (GLOBE NEWSWIRE) – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced the appointment of Jay S. Duker, M.D. as Chief Executive Officer (CEO). Dr. Duker has transitioned from his most recent role as Chief Operating Officer (COO) and President. Dr. Duker has also been appointed to the Board of Directors of the Company, effective today. Nancy S. Lurker has transitioned to the role of Executive Vice Chair of the Board of Directors from the position of CEO.

 

“Serving as CEO of EyePoint Pharmaceuticals these past seven years has been an exciting journey, and I am immensely proud of what our team has accomplished to create a brighter future for patients at risk of losing their sight. It has been a privilege to lead the growth of EyePoint into a best-in-class leader in sustained ocular drug delivery, advancing first-in-class therapeutics,” said Nancy Lurker, Executive Vice-Chair of EyePoint Pharmaceuticals. “We have accomplished a tremendous amount of value enhancing catalysts over the last several years including the advancement of EYPT-1901 into two oversubscribed Phase 2 trials, revenue growth for YUTIQ culminating in a successful sale of commercial rights to YUTIQ, and the significant strengthening of our balance sheet. With the transformation of EyePoint into a pure play drug development company, a compelling clinical pipeline, and recent financial and clinical achievements that put EyePoint in a position of strength, this is the right time to move into a new role. I have never been more excited about our potential and am deeply confident in the Company’s future under Jay’s leadership.”

 

Ms. Lurker continued, “Jay has been a tremendous partner and instrumental leader in his role as COO, helping to strengthen our organization as we progressed our pipeline of exciting and innovative ocular products, including reporting positive data for our Phase 1 DAVIO trial in wet AMD and the initiation of two Phase 2 trials for EYP-1901, our Phase 2 DAVIO2 trial in wet AMD and PAVIA trial in NPDR. I look forward to working with him as I continue my commitment to EyePoint as Executive Vice-Chair of the Board.”

 

“Jay is a world-renowned retinal specialist with a successful track record of founding ophthalmology companies. His clear vision and demonstrated ability to lead and execute, along with his clinical and retinal disease expertise make him uniquely qualified to continue to drive EyePoint’s growth as a leader in sustained ocular drug delivery. Jay’s background and deep knowledge of EyePoint, having served the Company in various roles for the past seven years, coupled with EyePoint’s sharpened focus on advancing our expanding retina pipeline, make him the ideal fit to assume the CEO position, and reflects the realization of EyePoint’s long-term CEO succession plan,” said Dr. Göran Ando, M.D., Chair of the Board of EyePoint Pharmaceuticals. “On behalf of EyePoint’s Board, we would like to thank Nancy for her outstanding leadership, under which the company achieved significant successes and is now well-positioned for continued growth and continuing to build value for our shareholders. Under her tenure, EyePoint saw the

 

 

successful US commercial launch of YUTIQ®, the pre-clinical, Phase 1 and ongoing Phase 2 clinical development of EYP-1901, the sale of YUTIQ, and a significantly strengthened balance sheet with over $250M raised along with $82.5M from the sale of YUTIQ. We look forward to her continued guidance and support of the Company in her new role as Executive Vice-Chair.”

 

“I am honored to become Chief Executive Officer of EyePoint at this exciting juncture as we advance our potentially game-changing treatment options for a variety of eye diseases and focus on expanding our pipeline by leveraging the sustained delivery capability of our Durasert E™ technology. As a physician whose career has been dedicated to improving outcomes in retinal disease, I am incredibly passionate about EyePoint’s mission of bringing innovative therapies to patients at risk of losing their sight,” said Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals. “I look forward to continuing to work with our top tier executive team and world-class board of directors to build on our recent achievements. With our strong balance sheet, the anticipated readouts of our two Phase Two trials of EYPT-1901 in wet AMD and NPDR during the next nine months and the planned initiation of a third Phase 2 trial in DME in the first quarter of 2024, EyePoint is well-positioned to grow as a leader in sustained ocular drug delivery and bring first-in-class therapeutics to patients.”

 

Dr. Duker served as an independent member of EyePoint’s Board of Directors from 2016 to 2020. He joined EyePoint as Chief Strategic Scientific Officer on a part-time basis in 2020 then transitioned to full time Chief Operating Officer (COO) in November of 2021. In his role as COO, Dr. Duker was responsible for overseeing all clinical development, research, product development and manufacturing. Dr. Duker has extensive experience with wide-ranging roles in clinical, research, business, start-ups, and academic settings. In addition to his earlier roles at EyePoint, Dr. Duker was the Director of the New England Eye Center and Chair of Ophthalmology at Tufts Medical Center and the Tufts University School of Medicine. Dr. Duker has co-founded three start-ups, including Hemera Biosciences, a gene therapy company that developed an anti-complement treatment for dry macular degeneration, which was acquired by Janssen in 2020. In addition, Dr. Duker was the Chair of the Board of Sesen Bio, a publicly traded clinical stage biopharmaceutical company. He has published more than 300 journal articles related to ophthalmology and is co-author of Yanoff and Duker’s Ophthalmology, a best-selling ophthalmic textbook. Dr. Duker received an A.B. from Harvard University and an M.D. from the Jefferson Medical College of Thomas Jefferson University.

 

About EyePoint Pharmaceuticals

 

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment currently in Phase 2 clinical trials. The proven Durasert® drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. For more information visit www.eyepointpharma.com.

 

 

EYEPOINT SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995.

 

 

Such statements include, but are not limited to, statements regarding the sufficiency of our existing cash resources into 2025; our plans and any other statements about future expectations, prospects, estimates and other matters that are dependent upon future events or developments, including statements containing the words “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint’s actual results to be materially different than those expressed in or implied by EyePoint’s forward-looking statements. For EyePoint, this includes uncertainties regarding our ability to realize the anticipated benefits of the 2023 sale of YUTIQ® to Alimera Sciences including our potential to receive additional payments from Alimera pursuant to the our agreements with Alimera; our ability to manufacture YUTIQ in sufficient quantities pursuant to our commercial supply agreements with Alimera and Ocumension Therapeutics; the timing and clinical development of our product candidates, including EYP-1901; the potential for EYP-1901 as a novel sustained delivery treatment for serious eye diseases, including wet age-related macular degeneration, non-proliferative diabetic retinopathy and diabetic macular edema; the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; the success of current and future license agreements, including our agreements with Alimera, Ocumension, Equinox Science and Betta Pharmaceuticals; termination or breach of current and future license agreements; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of competition; market acceptance of our products, including our out-licensed products; product liability; industry consolidation; compliance with environmental laws; risks and costs of international business operations; volatility of stock price; possible dilution; the impact of instability in general business and economic conditions, including changes in inflation, interest rates and the labor market; the extent to which COVID-19 impacts our business and the medical community; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; manufacturing risks; the sufficiency of the Company’s cash resources and need for additional financing; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated, or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated, or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

 

Investors:

Christina Tartaglia

Stern IR

Direct: 212-698-8700

christina.tartaglia@sternir.com

 

Media Contact:

Amy Phillips

Green Room Communications

Direct: 412-327-9499

aphillips@greenroompr.com

GRAPHIC 5 img96707757_0.jpg GRAPHIC begin 644 img96707757_0.jpg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end EX-101.LAB 6 eypt-20230710_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Securities Act File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.SCH 7 eypt-20230710.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 8 eypt-20230710_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 9 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document And Entity Information
Jul. 10, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 10, 2023
Entity Registrant Name EyePoint Pharmaceuticals, Inc.
Entity Central Index Key 0001314102
Entity Emerging Growth Company false
Securities Act File Number 000-51122
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 26-2774444
Entity Address, Address Line One 480 Pleasant Street
Entity Address, City or Town Watertown
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02472
City Area Code (617)
Local Phone Number 926-5000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001
Trading Symbol EYPT
Security Exchange Name NASDAQ
XML 10 eypt-20230710_htm.xml IDEA: XBRL DOCUMENT 0001314102 2023-07-10 2023-07-10 0001314102 false 8-K 2023-07-10 EyePoint Pharmaceuticals, Inc. DE 000-51122 26-2774444 480 Pleasant Street Watertown MA 02472 (617) 926-5000 false false false false Common Stock, par value $0.001 EYPT NASDAQ false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://eyepointpharma.com/20230710/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports eypt-20230710.htm eypt-20230710.xsd eypt-20230710_lab.xml eypt-20230710_pre.xml eypt-ex10_1.htm eypt-ex10_2.htm eypt-ex99_1.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "eypt-20230710.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "eypt-20230710.htm" ] }, "labelLink": { "local": [ "eypt-20230710_lab.xml" ] }, "presentationLink": { "local": [ "eypt-20230710_pre.xml" ] }, "schema": { "local": [ "eypt-20230710.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "eypt", "nsuri": "http://eyepointpharma.com/20230710", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "eypt-20230710.htm", "contextRef": "C_829a6f85-5d55-4d38-a8b3-ea5609e68ab6", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://eyepointpharma.com/20230710/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "eypt-20230710.htm", "contextRef": "C_829a6f85-5d55-4d38-a8b3-ea5609e68ab6", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eyepointpharma.com/20230710/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eyepointpharma.com/20230710/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eyepointpharma.com/20230710/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eyepointpharma.com/20230710/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eyepointpharma.com/20230710/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eyepointpharma.com/20230710/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eyepointpharma.com/20230710/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eyepointpharma.com/20230710/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eyepointpharma.com/20230710/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eyepointpharma.com/20230710/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eyepointpharma.com/20230710/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eyepointpharma.com/20230710/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eyepointpharma.com/20230710/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eyepointpharma.com/20230710/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eyepointpharma.com/20230710/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eyepointpharma.com/20230710/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eyepointpharma.com/20230710/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eyepointpharma.com/20230710/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eyepointpharma.com/20230710/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eyepointpharma.com/20230710/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eyepointpharma.com/20230710/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://eyepointpharma.com/20230710/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 17 0000950170-23-032324-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-032324-xbrl.zip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�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end